Patritumab deruxtecan (HER3-DXd) is an antibody-drug conjugate (ADC) designed for non-small cell lung cancer (NSCLC) research. It comprises a humanized anti-HER3 antibody conjugated via a cleavable linker to a topoisomerase I inhibitor payload (DXd). This ADC is utilized in preclinical studies to investigate targeted cytotoxicity in both in vitro and in vivo HER3-expressing cancer models.
Concentration:
10.45 mg/mL
Molecular Weight:
155.2 kDa
Purity:
95.00% (May vary between batches)
CAS Number:
[2227102-46-5]
Target:
Antibody-Drug Conjugates (ADCs)
* VAT and and shipping costs not included. Errors and price changes excepted